Anebulo Pharmaceuticals Inc (ANEB)

$1.42 -0.05 (-3.40%)
Market Cap 60.40M
Revenue (ttm) 0.00
Net Income (ttm) -8.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,000
Avg Vol 9,250
Day's Range N/A - N/A
Shares Out 41.09M
Stochastic %K 43%
Beta -1.15
Analysts Strong Sell
Price Target $4.00

Company Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2...

Industry: Biotechnology
Sector: Healthcare
Phone: 512 598 0931
Address:
1017 Ranch Road 620 South, Suite 107, Lakeway, United States
PenkeTrading
PenkeTrading Jun. 14 at 4:39 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Anebulo Pharmaceuticals Inc. Is that bullish or bearish? $ANEB #Anebulo #RsiOverbought #NASDAQ
0 · Reply
JB20901
JB20901 Jun. 4 at 4:26 PM
$ANEB interesting shape
0 · Reply
Ulfric
Ulfric Jun. 2 at 8:20 PM
$ANEB ☕️
0 · Reply
HOMACRON
HOMACRON May. 16 at 9:37 PM
$ANEB had this on my watch list for a while. Not trading it but curious if there's been bad developments w the clinicals? does it now work?
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 5:14 PM
Maxim Group has updated their rating for Anebulo Pharmaceuticals ( $ANEB ) to Buy with a price target of 3.
0 · Reply
d_risk
d_risk May. 14 at 1:43 AM
$ANEB - Anebulo Pharmaceuticals, Inc. - 10Q - Updated Risk Factors ANEB’s 10-Q updates show a $1.6M rise in accumulated deficit, refined drug development risks, added capital raising challenges, new Nasdaq compliance issues now resolved, and removal of trade policy risks; core risk categories remain stable. #Biotechnology #FinancialRisk #RegulatoryCompliance #CapitalRaising #DrugDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/ANEB/10-Q/2025-05-13
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 6:54 AM
$ANEB Intriguing play in cannabis toxicity treatment. FDA support looks promising. Phase 1 study coming soon. Potential game-changer for pediatric cannabis exposure. Keeping close eye on ANEB's development trajectory. insightful article: https://beyondspx.com/article/anebulo-pharmaceuticals-nasdaq-aneb-rapidly-advancing-a-novel-solution-for-acute-cannabis-toxicity
0 · Reply
Fib7867
Fib7867 Mar. 22 at 7:20 PM
#myANEBanalysis $ANEB
0 · Reply
RAClose
RAClose Mar. 20 at 4:28 AM
$ANEB ; $MILYS >>MAYBE<< is the operative word since these are up +100% since 3/3/35. Must be careful with ANEB (after hours its showing down, but this has happened in the past and it recovered big. $RDUS +128% since 3/3/35. I have NOT traded these yet, just found them. Be Careful,
1 · Reply
BearishNinjaTrader
BearishNinjaTrader Mar. 11 at 8:01 PM
$ANEB Shorted this into close, follow for more.
0 · Reply
Latest News on ANEB
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

May 13, 2025, 4:05 PM EDT - 6 weeks ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Feb 14, 2025, 4:05 PM EST - 4 months ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Dec 23, 2024, 9:15 AM EST - 6 months ago

Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Nov 13, 2024, 4:05 PM EST - 8 months ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Sep 25, 2024, 4:05 PM EDT - 9 months ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Jul 22, 2024, 7:00 AM EDT - 1 year ago

Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

May 15, 2024, 1:15 PM EDT - 1 year ago

Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

May 15, 2024, 1:05 PM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Feb 13, 2024, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Nov 14, 2023, 4:05 PM EST - 1 year ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Oct 6, 2023, 4:06 PM EDT - 1 year ago

Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors

Anebulo Pharmaceuticals Announces New CEO

Oct 6, 2023, 4:06 PM EDT - 1 year ago

Anebulo Pharmaceuticals Announces New CEO

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Sep 20, 2023, 4:29 PM EDT - 1 year ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Aug 30, 2023, 8:00 AM EDT - 1 year ago

Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

May 11, 2023, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Mar 8, 2023, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Expands its Integrated and Outsourced Solutions

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Feb 10, 2023, 8:38 AM EST - 2 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Jan 27, 2023, 3:49 PM EST - 2 years ago

Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Jan 9, 2023, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Nov 10, 2022, 8:00 AM EST - 2 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Nov 1, 2022, 4:00 PM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Sep 26, 2022, 7:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Announces $6.6 Million Private Placement Financing

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Sep 26, 2022, 7:00 AM EDT - 2 years ago

Anebulo Pharmaceuticals Announces Positive Interim Data for ANEB-001 from Part B of its Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Sep 20, 2022, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals to Webcast R&D Day on September 26, 2022

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Sep 9, 2022, 8:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Aug 23, 2022, 5:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals to Host Inaugural R&D Day in New York City on Monday, September 26

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Jul 5, 2022, 8:00 AM EDT - 3 years ago

Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Jul 5, 2022, 6:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Jun 23, 2022, 4:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

May 24, 2022, 4:00 PM EDT - 3 years ago

Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

May 11, 2022, 9:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Apr 1, 2022, 7:00 AM EDT - 3 years ago

Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Feb 11, 2022, 9:13 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Feb 11, 2022, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Jan 6, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Jan 6, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Jan 4, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Jan 3, 2022, 7:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Nov 12, 2021, 8:00 AM EST - 3 years ago

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

Oct 13, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Announces Issuance of U.S. Patent Covering Use of ANEB-001 for the Treatment of Acute Cannabinoid Overdose

Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem

Oct 12, 2021, 8:59 AM EDT - 4 years ago

Overdose Unknown: How Anebulo Pharmaceuticals Is Working to Solve a Growing Marijuana Overdose Problem

CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials

Sep 23, 2021, 10:49 AM EDT - 4 years ago

CBD-Focused Anebulo Pharma Posts Q4 & Full Year 2021 Earnings, Launching Phase 2 Cannabis Overdose Clinical Trials

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

Sep 22, 2021, 4:05 PM EDT - 4 years ago

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update

Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Sep 13, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Announces Completion of Manufacturing of ANEB-001 Capsules for Upcoming Phase 2 Clinical Trial

Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 7, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members

Aug 12, 2021, 8:00 AM EDT - 4 years ago

Anebulo Pharmaceuticals Announces Formation of Scientific Advisory Board, Names First Two Members

Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials

Jun 22, 2021, 10:27 AM EDT - 4 years ago

Cannabinoid-Focused Anebulo Pharma Posts Q3 Earnings, On Schedule To Start Cannabis Overdose Clinical Trials

Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results

Jun 21, 2021, 4:05 PM EDT - 4 years ago

Anebulo Pharmaceuticals Reports Recent Business Highlights and Announces Third Quarter Fiscal Year 2021 Financial Results

U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week

May 8, 2021, 11:29 PM EDT - 4 years ago

U.S. IPO Weekly Recap: Sacramento Bank Five Star Bancorp Finishes On Top In An 8 IPO Week

FSBC BWMN HNST WDH

PenkeTrading
PenkeTrading Jun. 14 at 4:39 AM
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Anebulo Pharmaceuticals Inc. Is that bullish or bearish? $ANEB #Anebulo #RsiOverbought #NASDAQ
0 · Reply
JB20901
JB20901 Jun. 4 at 4:26 PM
$ANEB interesting shape
0 · Reply
Ulfric
Ulfric Jun. 2 at 8:20 PM
$ANEB ☕️
0 · Reply
HOMACRON
HOMACRON May. 16 at 9:37 PM
$ANEB had this on my watch list for a while. Not trading it but curious if there's been bad developments w the clinicals? does it now work?
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 5:14 PM
Maxim Group has updated their rating for Anebulo Pharmaceuticals ( $ANEB ) to Buy with a price target of 3.
0 · Reply
d_risk
d_risk May. 14 at 1:43 AM
$ANEB - Anebulo Pharmaceuticals, Inc. - 10Q - Updated Risk Factors ANEB’s 10-Q updates show a $1.6M rise in accumulated deficit, refined drug development risks, added capital raising challenges, new Nasdaq compliance issues now resolved, and removal of trade policy risks; core risk categories remain stable. #Biotechnology #FinancialRisk #RegulatoryCompliance #CapitalRaising #DrugDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/ANEB/10-Q/2025-05-13
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 6:54 AM
$ANEB Intriguing play in cannabis toxicity treatment. FDA support looks promising. Phase 1 study coming soon. Potential game-changer for pediatric cannabis exposure. Keeping close eye on ANEB's development trajectory. insightful article: https://beyondspx.com/article/anebulo-pharmaceuticals-nasdaq-aneb-rapidly-advancing-a-novel-solution-for-acute-cannabis-toxicity
0 · Reply
Fib7867
Fib7867 Mar. 22 at 7:20 PM
#myANEBanalysis $ANEB
0 · Reply
RAClose
RAClose Mar. 20 at 4:28 AM
$ANEB ; $MILYS >>MAYBE<< is the operative word since these are up +100% since 3/3/35. Must be careful with ANEB (after hours its showing down, but this has happened in the past and it recovered big. $RDUS +128% since 3/3/35. I have NOT traded these yet, just found them. Be Careful,
1 · Reply
BearishNinjaTrader
BearishNinjaTrader Mar. 11 at 8:01 PM
$ANEB Shorted this into close, follow for more.
0 · Reply
Rvazstocksfl
Rvazstocksfl Mar. 11 at 7:38 PM
$ANEB lol
0 · Reply
Rvazstocksfl
Rvazstocksfl Mar. 11 at 7:34 PM
$ANEB why this trash is up ?
0 · Reply
ajmrtxl
ajmrtxl Mar. 7 at 4:53 PM
$ANEB's latest data on SqueezeFinder
0 · Reply
PenkeTrading
PenkeTrading Mar. 5 at 3:28 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Anebulo Pharmaceuticals Inc. Is that bullish or bearish? $ANEB #Anebulo #RsiOversold #NASDAQ
0 · Reply
caprihunter
caprihunter Feb. 19 at 11:53 AM
$GPUS All right just watch $TRUG $ANEB $SRXH $GB
0 · Reply
luckyRoy7
luckyRoy7 Jan. 3 at 3:57 PM
$ANEB felt like it was building energy all day. These moments of coiled setups often lead to interesting next day moves.
0 · Reply
MissFred
MissFred Dec. 31 at 8:24 PM
$ANEB Getting banged in 2025
0 · Reply
leteetride
leteetride Dec. 27 at 5:22 PM
$ANEB Insider Aron English just bought 10 million shares
0 · Reply
Tabinvest
Tabinvest Dec. 23 at 4:06 PM
$ANEB anyone care to share short interest and rate in this one Thanks
0 · Reply
fastmoneytraders
fastmoneytraders Dec. 23 at 2:18 PM
shorted $ANEB 1.72 covered 1.35
2 · Reply
Scanners_Free
Scanners_Free Dec. 23 at 2:16 PM
$ANEB NNNNNNNEEEEEEEEWSSSSS
0 · Reply
itsphd
itsphd Dec. 20 at 9:34 PM
$ANEB cant predict near term pricing, the thesis for this stock into mid 2025 is if Trump legalizes weed for recreational use federally to combat the Mexican cartels that likely will also get listed as terrorist organizations. If so this drug could have a wider market segment to penetrate.
0 · Reply